MGNX News and Press, MacroGenics Inc. From 11/06/19

SAN FRANCISCO, CA / ACCESSWIRE / November 6, 2019 / Hagens Berman urges MacroGenics (NASDAQ: MGNX) investors who have suffered losses in excess of $50,000 to submit their loss now to learn if they qualify to recover their investment losses. The November 12, 2019 lead plaintiff deadline...

MacroGenics (NASDAQ: MGNX ): Q3 GAAP EPS of -$0.91 beats by $0.02 . More news on: MacroGenics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

ROCKVILLE, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progr...

ROCKVILLE, MD, Nov. 06, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the clinical and preclinical ...

SAN FRANCISCO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics (NASDAQ: MGNX) investors who have suffered losses in excess of $50,000 to submit their loss now to learn if they qualify to recover their investment losses.  The November 12, 2019 lead plaintiff de...

Class-action law firm urges MGNX investors who have suffered losses of $50K+ to submit your loss now to learn if they qualify to recover their investment losses. SAN FRANCISCO, CA / ACCESSWIRE / November 4, 2019 / Hagens Berman reminds investors in MacroGenics (NASD...

Background I turned bearish on Incyte ( INCY ) in early May 2017, with summary comments in an article on it including the following: Even though the stock looked good in the $117-118 range on the way up a few months ago, there are more negatives now... Thus, while INCY is "in play" a...

Rockville, MD, Oct. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release...

One out of every eight women in the United States will develop breast cancer, according to Breastcancer.org. Of those, about 25% will have an aggressive type called "HER2-positive," which also recurs at higher rates. The human epidermal growth factor receptor 2 (HER2) gene produces proteins tha...

SHANGHAI, China and SAN FRANCISCO, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that its partner MacroGenics, Inc. (NASDAQ: MGNX) has dosed the first patient in the Phase 2/3 M...